CLADRIBINE for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 581 adverse event reports in the FDA FAERS database where CLADRIBINE was used for Relapsing-remitting multiple sclerosis.
Most Reported Side Effects for CLADRIBINE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 696 | 9.3% | 4 | 77 |
| Headache | 579 | 7.7% | 2 | 53 |
| Lymphocyte count decreased | 448 | 6.0% | 3 | 125 |
| Multiple sclerosis relapse | 404 | 5.4% | 2 | 151 |
| Nausea | 354 | 4.7% | 5 | 53 |
| Pneumonia | 318 | 4.2% | 35 | 121 |
| White blood cell count decreased | 311 | 4.1% | 3 | 64 |
| Urinary tract infection | 242 | 3.2% | 6 | 132 |
| Pyrexia | 207 | 2.8% | 20 | 115 |
| Multiple sclerosis | 206 | 2.7% | 4 | 60 |
| Off label use | 197 | 2.6% | 34 | 48 |
| Asthenia | 195 | 2.6% | 6 | 68 |
| Drug ineffective | 189 | 2.5% | 32 | 38 |
| Lymphopenia | 188 | 2.5% | 2 | 52 |
| Covid-19 | 179 | 2.4% | 15 | 72 |
Other Indications for CLADRIBINE
Multiple sclerosis (5,360)
Hairy cell leukaemia (331)
Acute myeloid leukaemia (281)
Product used for unknown indication (162)
Relapsing multiple sclerosis (123)
Langerhans' cell histiocytosis (116)
Chronic lymphocytic leukaemia (38)
Secondary progressive multiple sclerosis (32)
Rosai-dorfman syndrome (20)
Erdheim-chester disease (17)
Other Drugs Used for Relapsing-remitting multiple sclerosis
OCRELIZUMAB (15,658)
FINGOLIMOD (8,814)
OFATUMUMAB (3,864)
DIMETHYL (3,638)
NATALIZUMAB (2,749)
INTERFERON BETA-1A (2,058)
GLATIRAMER (1,965)
ALEMTUZUMAB (1,604)
TERIFLUNOMIDE (1,320)
RITUXIMAB (956)